IF0 Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
InflaRx N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.94 |
| 52 Week High | US$4.91 |
| 52 Week Low | US$0.93 |
| Beta | 1.09 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -33.51% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -0.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| IF0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -33.5% | -17.2% | 8.2% |
Return vs Industry: IF0 underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: IF0 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| IF0 volatility | |
|---|---|
| IF0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: IF0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IF0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 56 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
InflaRx N.V. Fundamentals Summary
| IF0 fundamental statistics | |
|---|---|
| Market cap | €109.35m |
| Earnings (TTM) | -€34.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs IF0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IF0 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €34.13m |
| Earnings | -€34.13m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IF0 perform over the long term?
See historical performance and comparison